JP2014521310A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521310A5
JP2014521310A5 JP2014516066A JP2014516066A JP2014521310A5 JP 2014521310 A5 JP2014521310 A5 JP 2014521310A5 JP 2014516066 A JP2014516066 A JP 2014516066A JP 2014516066 A JP2014516066 A JP 2014516066A JP 2014521310 A5 JP2014521310 A5 JP 2014521310A5
Authority
JP
Japan
Prior art keywords
wing segment
compound
modified
sugar
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014516066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521310A (ja
JP6043347B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/042813 external-priority patent/WO2012174476A2/en
Publication of JP2014521310A publication Critical patent/JP2014521310A/ja
Publication of JP2014521310A5 publication Critical patent/JP2014521310A5/ja
Application granted granted Critical
Publication of JP6043347B2 publication Critical patent/JP6043347B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014516066A 2011-06-16 2012-06-15 線維芽細胞増殖因子受容体4の発現のアンチセンス調節 Expired - Fee Related JP6043347B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161497921P 2011-06-16 2011-06-16
US61/497,921 2011-06-16
PCT/US2012/042813 WO2012174476A2 (en) 2011-06-16 2012-06-15 Antisense modulation of fibroblast growth factor receptor 4 expression

Publications (3)

Publication Number Publication Date
JP2014521310A JP2014521310A (ja) 2014-08-28
JP2014521310A5 true JP2014521310A5 (enExample) 2015-07-09
JP6043347B2 JP6043347B2 (ja) 2016-12-14

Family

ID=47357786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014516066A Expired - Fee Related JP6043347B2 (ja) 2011-06-16 2012-06-15 線維芽細胞増殖因子受容体4の発現のアンチセンス調節

Country Status (7)

Country Link
US (2) US8933213B2 (enExample)
EP (1) EP2721156B1 (enExample)
JP (1) JP6043347B2 (enExample)
CN (1) CN103597074A (enExample)
AU (1) AU2012271357A1 (enExample)
CA (1) CA2839437A1 (enExample)
WO (1) WO2012174476A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177481A2 (en) * 2011-06-24 2012-12-27 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
WO2014076196A1 (en) 2012-11-15 2014-05-22 Santaris Pharma A/S Anti apob antisense conjugate compounds
CA2893801A1 (en) 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
AU2014222150A1 (en) 2013-03-01 2015-09-10 National University Corporation Tokyo Medical And Dental University Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
RU2670614C9 (ru) 2013-05-01 2018-11-23 Ионис Фармасьютикалз, Инк. Композиции и способы модулирования экспрессии hbv и ttr
JP6667453B2 (ja) 2014-05-01 2020-03-18 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. 成長ホルモン受容体発現を調節するための組成物及び方法
CN105886473B (zh) * 2015-01-26 2021-05-07 温州医科大学 一种稳定沉默fgfr4基因表达的肝癌细胞株的制备方法
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
US11279697B2 (en) 2017-09-05 2022-03-22 Bioardis Llc Aromatic derivative, preparation method for same, and medical applications thereof
WO2020177067A1 (en) 2019-03-05 2020-09-10 Bioardis Llc Aromatic derivatives, preparation methods, and medical uses thereof
US10871958B1 (en) * 2019-07-03 2020-12-22 Capital One Services, Llc Techniques to perform applet programming

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
EP0420081A1 (en) 1989-09-26 1991-04-03 Takeda Chemical Industries, Ltd. Monoclonal antibody against an acidic FGF protein, its production and use
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US20040006005A1 (en) 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
JPH08504559A (ja) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド 個別に制御される冗長巻線を有するモータシステム
WO1994015945A1 (en) 1992-12-31 1994-07-21 Texas Biotechnology Corporation Antisense molecules directed against a fibroflast growth factor receptor gene family
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US20050053976A1 (en) 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
WO2001018210A1 (en) 1999-09-08 2001-03-15 Genentech, Inc. Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
ATE293123T1 (de) 1997-09-12 2005-04-15 Exiqon As Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
ATE212552T1 (de) 1998-04-17 2002-02-15 Tufts College Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten
DK199800393U1 (da) 1998-10-21 1998-10-21 R E Beton A S Betonelementfabr Tagelement
US6153432A (en) 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
CA2372085C (en) 1999-05-04 2009-10-27 Exiqon A/S L-ribo-lna analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
WO2000071129A1 (en) 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
WO2001049849A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf11
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
JP2003527858A (ja) 2000-03-22 2003-09-24 アムジェン インコーポレイテッド 線維芽細胞増殖因子レセプター様分子およびその使用
US20020001825A1 (en) 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
IL152785A0 (en) 2000-05-12 2003-06-24 Univ Utah Res Found Compositions and methods for cell dedifferentiation and tissue regeneration
EP1202065A1 (en) 2000-10-25 2002-05-02 Aventis Pharma S.A. Net, a transcription factor of the TCF family, as regulator of angiogenic expression.
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
DE10152147A1 (de) 2001-10-25 2003-05-15 Chemogenix Gmbh Verfahren zum Aufbringen von Nukleosiden und/oder Nukleotiden auf funktionalisierten Oberflächen sowie Verfahren zur Bestimmung von Kopplungsausbeuten bei der Synthese von Nukleotiden
EP1441725A1 (en) 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
US7655397B2 (en) 2002-04-25 2010-02-02 The United States Of America As Represented By The Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
IL165264A0 (en) 2002-05-23 2005-12-18 Cytopia Pty Ltd Protein kinase inhibitors
TW200401638A (en) 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
NZ537208A (en) 2002-06-27 2009-02-28 Adipogen Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
JP4758099B2 (ja) 2002-07-08 2011-08-24 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 反射型立体ディスプレイ
WO2004041277A1 (en) 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP2213738B1 (en) 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
US7250289B2 (en) * 2002-11-20 2007-07-31 Affymetrix, Inc. Methods of genetic analysis of mouse
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
US20050048494A1 (en) 2003-08-28 2005-03-03 Yixin Wang Colorectal cancer prognostics
JP4731324B2 (ja) 2003-08-28 2011-07-20 武 今西 N−o結合性架橋構造型新規人工核酸
WO2005027962A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
EP1680140B1 (en) 2003-10-16 2011-04-20 Imclone LLC Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
CA2550245A1 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
WO2005076998A2 (en) 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
AU2005213485A1 (en) 2004-02-05 2005-08-25 Intradigm Corporation Methods and compositions for combination RNAi therapeutics
AU2005295756B2 (en) 2004-10-13 2012-02-02 Isis Parmaceuticals, Inc. Antisense modulation of PTP1B expression
EP1984381B1 (en) 2006-01-27 2010-09-29 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
DK2066684T3 (da) 2006-05-11 2012-10-22 Isis Pharmaceuticals Inc 5´-Modificerede bicycliske nukleinsyreanaloge
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
EP2125852B1 (en) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
WO2008109372A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting pdgf gene expression and uses thereof
WO2008109369A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
AU2008260277C1 (en) 2007-05-30 2014-04-17 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
CN101796062B (zh) 2007-07-05 2014-07-30 Isis制药公司 6-双取代双环核酸类似物
US8486904B2 (en) * 2007-10-01 2013-07-16 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
EP3626823A1 (en) * 2009-09-11 2020-03-25 Ionis Pharmaceuticals, Inc. Modulation of huntingtin expression
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping

Similar Documents

Publication Publication Date Title
JP2014521310A5 (enExample)
JP2012505660A5 (enExample)
JP2014530004A5 (enExample)
JP2015501155A5 (enExample)
JP2014511686A5 (enExample)
JP2020022483A5 (enExample)
JP2016501513A5 (enExample)
JP2018199700A5 (enExample)
JP2017513469A5 (enExample)
JP2014513954A5 (enExample)
JP2018126141A5 (enExample)
JP2016528891A5 (enExample)
JP2019088329A5 (enExample)
RU2501803C2 (ru) Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4)
JP2015507625A5 (enExample)
RU2017120536A (ru) Способы и композиции для модулирования экспрессии аполипопротеина (а)
JP2017510271A5 (enExample)
RU2016116849A (ru) Композиции для модуляции экспрессии c90rf72
JP2013538560A5 (enExample)
JP2017505116A5 (enExample)
JP2012050438A5 (enExample)
RU2019130898A (ru) Композиции для модуляции экспрессии атаксина 2
JP2016116520A5 (enExample)
RU2016130110A (ru) Способы хирургической обработки путем резания и сшивания скобками
JP2016523548A5 (enExample)